A detailed history of Perceptive Advisors LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 2,125,649 shares of AMLX stock, worth $9.06 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
2,125,649
Holding current value
$9.06 Million
% of portfolio
0.18%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.65 - $3.24 $3.51 Million - $6.89 Million
2,125,649 New
2,125,649 $6.89 Million
Q1 2024

May 15, 2024

SELL
$2.71 - $19.57 $4.25 Million - $30.7 Million
-1,569,125 Reduced 83.95%
300,000 $852,000
Q4 2023

Feb 14, 2024

SELL
$12.07 - $18.46 $9.89 Million - $15.1 Million
-819,748 Reduced 30.49%
1,869,125 $27.5 Million
Q3 2023

Nov 14, 2023

SELL
$18.08 - $23.45 $39.5 Million - $51.2 Million
-2,185,046 Reduced 44.83%
2,688,873 $49.2 Million
Q2 2023

Aug 14, 2023

SELL
$20.98 - $31.42 $24.4 Million - $36.5 Million
-1,160,725 Reduced 19.23%
4,873,919 $105 Million
Q1 2023

May 15, 2023

SELL
$27.71 - $40.93 $1.49 Million - $2.2 Million
-53,689 Reduced 0.88%
6,034,644 $177 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $18.3 Million - $24.2 Million
616,300 Added 11.26%
6,088,333 $225 Million
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $33.1 Million - $59.7 Million
1,931,625 Added 54.56%
5,472,033 $154 Million
Q2 2022

Aug 15, 2022

BUY
$6.85 - $19.93 $14.2 Million - $41.2 Million
2,066,301 Added 140.17%
3,540,408 $68.2 Million
Q1 2022

May 16, 2022

BUY
$12.85 - $32.9 $18.9 Million - $48.5 Million
1,474,107 New
1,474,107 $18.9 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $249M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.